Fig. 2.

CONSORT diagram: disposition of enrolled metastatic breast cancer patients. ^aTwo deaths were disease progression, and the third death was reported as respiratory compromise. ^bPatients with stable disease at week 12 continued on open-label cabozantinib after randomization was suspended upon recommendation of the independent study oversight committee